Navigation Links
Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease
Date:12/1/2008

Baby Girl with Hypophosphatasia Treated With ENB-0040 at Children's Hospital, Health Sciences Centre in Winnipeg

MONTREAL, Dec. 1 /PRNewswire/ -- Enobia Pharma, an emerging Canadian biotech company focused on developing novel therapeutics for serious bone disorders, today announced that the first infant patient in its clinical program for hypophosphatasia was dosed. Enobia is investigating Enzyme Replacement Therapy (ERT) with ENB-0040 for the treatment of this rare and often crippling genetic bone disorder for which there is no approved treatment.

"Our enzyme replacement therapy program for hypophosphatasia has progressed well," said Robert Heft, CEO of Enobia. "Based upon the excellent preclinical data we are hopeful that hypophosphatasia patients will benefit from treatment with ENB-0040. We're grateful for everyone involved in expediting the treatment of this patient."

Under two separate protocols, ENB-0040 will be evaluated in both adults and infants afflicted with hypophosphatasia at sites in Canada and the United States. In August, physicians at the University of Manitoba dosed the first adult patient as part of that cohort to evaluate the safety, tolerability and pharmacokinetics of ENB-0040.

Enobia Pharma is pleased to reproduce below today's announcement made by Children's Hospital, Health Sciences Centre Winnipeg regarding the dosing of the first infant patient in the early ENB-0040 studies.

    CHILD RECEIVING POTENTIALLY LIFE-SAVING TREATMENT AT HSC AS PART OF INTERNATIONAL DRUG TRIAL

    Infant Girl From Belfast Flown To Winnipeg

WINNIPEG - A 9-month-old baby girl from Belfast is receiving potentially life-saving experimental treatment at Children's Hospital, Health Sciences Centre Winnipeg as part of an international drug trial.

The child has a bone disorde
'/>"/>

SOURCE Enobia Pharma Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team
2. Enobia Pharma Receives FDA Orphan Drug Designation for Hypophosphatasia Product Candidate ENB-0040
3. Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia
4. PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R)
5. Addrenex Pharmaceuticals Initiates Phase 2 Trial on Its Novel Hypertension Drug, ADX415
6. CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM)
7. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neulasta(R)
8. Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology
9. Baxter Initiates Phase III Trial for the Treatment of Alzheimers Disease
10. S*BIO Initiates U.S. Phase I Clinical Trials of Oral JAK2 Inhibitor SB1518 for the Treatment of Hematological Malignancies
11. Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... The quantum dot market report analyzes the ecosystem of the ... product includes medical devices, display, and others. The others segment ... storage, QD laser, and transistor. The application segment covers the ... The report also provides the geographic view for major regions ... Europe , Asia-Pacific (APAC), and ...
(Date:9/2/2015)... , Sept. 2, 2015 About Duchenne ... X-linked disease, which generally affects the male population. ... weakness. The disease is caused due to mutations ... lack of production of dystrophin (a protein essential ... lack of dystrophin weakens muscle function, causes loss ...
(Date:9/2/2015)... Sept. 2, 2015  Array BioPharma Inc. (Nasdaq: ... Executive Officer, Ron Squarer , will present ... Boston.  The public is welcome to participate in ... BioPharma website.Event: Wells Fargo Securities Healthcare ConferencePresenter: Ron ... 2015Time:  , 10:20 a.m. Eastern Time Webcast: ...
Breaking Medicine Technology:Quantum Dot Market by Product , Material, Application, and Geography- Forecast up to 2020 2Global Duchenne Muscular Dystrophy Drugs Market 2015-2019 2Global Duchenne Muscular Dystrophy Drugs Market 2015-2019 3
... May 25, 2011 Each month, millions of women suffer ... of the all-new AZO PMS™ -- the only ... women can now get relief from PMS with a fast ... PMS refers to a wide range of physical ...
... May 25, 2011 Graymark Healthcare, Inc. (NASDAQ: ... services and an innovator in comprehensive care for obstructive sleep ... 1-for-4 reverse stock split, which will be effective after the ... The 1-for-4 reverse stock split will automatically convert all shares ...
Cached Medicine Technology:New AZO PMS™ Delivers Fast, Natural Relief from Symptoms Associated with Premenstrual Syndrome 2New AZO PMS™ Delivers Fast, Natural Relief from Symptoms Associated with Premenstrual Syndrome 3Graymark Announces 1-for-4 Reverse Stock Split 2
(Date:9/2/2015)... ... September 03, 2015 , ... The Aspen Clinic (TAC), located ... geared towards kick-starting and inspiring wellness in the Roaring Fork Valley and beyond. , ... a whole mind-body approach to fitness - we are much more than a gym. ...
(Date:9/2/2015)... ... September 03, 2015 , ... Each year, the editors ... public servants, activists, corporate executives, entrepreneurs, health care professionals, and others have had ... led the magazine to tap the National League for Nursing’s outspoken CEO, ...
(Date:9/2/2015)... ... 02, 2015 , ... Healthegy, a leading producer of conferences, ... will deliver keynote presentations at the upcoming Digital Healthcare Innovation Summit ( http://www.digitalhealthcaresummit.com/ ... , Larry Renfro, CEO of Optum, will deliver the morning address. In his ...
(Date:9/2/2015)... , ... September 02, 2015 , ... ... gift from the Abraham and Mildred Goldstein Charitable Trust to establish the Abraham ... the gift comes six months after WCHN recruited nationally known gynecologic oncologist Thomas ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... efficacy endpoint data collection, cloud analytics and workflow solutions today announced the ... enables pharmaceutical researchers to participate in interactive programs in which ERT scientists ...
Breaking Medicine News(10 mins):Health News:TAC Introduces New Retreats for Fall Fitness 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 3Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 2Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 3Health News:Western Connecticut Health Network Receives $1 Million Gift to Establish Ovarian Cancer Research Endowment 2Health News:Western Connecticut Health Network Receives $1 Million Gift to Establish Ovarian Cancer Research Endowment 3Health News:ERT Announces Web Seminar Series on Optimizing Trial Data Collection & Gaining Real-Time Data Insights 2Health News:ERT Announces Web Seminar Series on Optimizing Trial Data Collection & Gaining Real-Time Data Insights 3
... News) -- New research finds that adults who suffered from ... fever -- are nine times more likely to have allergic ... are based on about 1,400 adults who have been followed ... Study. The study participants were assessed in 1968, when they ...
... TUESDAY, April 19 (HealthDay News) -- About 1 in ... -- meaning the virus becomes resistant to multiple drugs ... European study shows. That drug failure rate is ... maintaining viral load suppression in young patients who begin ...
... Amanda Gardner HealthDay Reporter , TUESDAY, April 19 ... for the diagnosis of Alzheimer,s disease could double the number ... guidelines, issued Tuesday by the Alzheimer,s Association and the U.S. ... the last recommendations, which have been in use since 1984. ...
... TUESDAY, April 19 (HealthDay News) -- People who have ... hospital than they did almost two decades ago, but discharges ... a result, Iowa researchers report. Using Medicare data on ... 2008, the researchers found that hospital stays are now averaging ...
... available in French . , Montreal April ... age, yet the reasons for this increasing forgetfulness have not ... older individuals have reduced learning and memory because their minds ... Published in The Quarterly Journal of Experimental Psychology, ...
... Goodwin HealthDay Reporter , TUESDAY, April 19 (HealthDay ... either had or were going to get all of the ... doctor,s advice on immunizations, two new surveys find. Pediatricians ... years of hype about a supposed autism/MMR (measles, mumps, rubella) ...
Cached Medicine News:Health News:Kids' Eczema, Hay Fever Linked to Allergic Asthma Later 2Health News:Children With HIV at Higher Risk of Drug Resistance 2Health News: Alzheimer's Cases Could Double With New Guidelines: Expert 2Health News: Alzheimer's Cases Could Double With New Guidelines: Expert 3Health News:Shorter Hospital Stays, More Readmissions After Hip Replacements 2Health News:Shorter Hospital Stays, More Readmissions After Hip Replacements 3Health News:Spring-cleaning the mind? 2Health News:Most Parents Vaccinate Kids, Trust Docs' Advice on Shots 2Health News:Most Parents Vaccinate Kids, Trust Docs' Advice on Shots 3
Inquire...
Inquire...
... EDTA K2 or EDTA K3 tubes. ... therefore blocks the coagulation cascade. Erythrocytes, ... anticoagulated blood sample are stable for ... are for the examination of whole ...
... the most powerful, productive ... and rich in features, ... a comprehensive authoring environment ... custom interactive multimedia content ...
Medicine Products: